Management of refractory OAB in the non-neurogenic patient

Curr Urol Rep. 2014 Sep;15(9):438. doi: 10.1007/s11934-014-0438-x.

Abstract

Overactive bladder (OAB) is one of the most common bothersome urological diseases. It also has a negative economic impact. Pathophysiology entails changes in neurogenic and myogenic factors, as well as urinary biomarkers such as nerve growth factor (NGF) and prostaglandins (PGs). With symptoms from OAB-Dry to OAB-Wet, the urodynamic pattern of OAB bladder is often characterized by idiopathic detrusor overactivity with lower threshold of sensation, diminished compliance and capacity. Treatment ranges from a combination of behavioral modifications (BM)/ pelvic floor muscle training (PFMT) to combinations of antimuscarinics, Botox injection, nerve stimulation and augmentation cystoplasty. Herein, a contemporary review on the different aspects of management of refractory OAB in patients without neuropathic disorders is presented.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A / therapeutic use*
  • Electric Stimulation Therapy / methods*
  • Humans
  • Muscarinic Antagonists / therapeutic use*
  • Neuromuscular Agents / therapeutic use*
  • Pelvic Floor
  • Physical Therapy Modalities*
  • Urinary Bladder / surgery*
  • Urinary Bladder, Overactive / therapy*

Substances

  • Muscarinic Antagonists
  • Neuromuscular Agents
  • Botulinum Toxins, Type A